GSK Bio
NEWS
Biopharma companies strengthen their executive ranks and boards with new additions.
Kadans expands its presence in the United Kingdom by adding its second research hub in the country to its Pan-European science park portfolio.
Jack Bailey, head of the company’s U.S. pharmaceuticals business is stepping down at the end of the year.
A new UK-based biotech company, AstronauTx Ltd, which builds on the work from the Alzheimer’s Research UK UCL Drug Discovery Institute (DDI), has received an investment of £6.5 million from the Dementia Discovery Fund (DDF).
Biopharma companies strengthen their senior leadership teams and boards of directors.
The vaccines are for Ebola Zaire, Ebola Sudan and the Marburg virus. Currently no licensed vaccines against these three viruses are available. All three diseases have a death rate of about 50%.
The new company will be helmed by Mylan’s Michael Goettler and is expected to generate 2020 revenues of $19 to $20 billion.
Here’s a look at the top clinical trial news from last week, with updates from Neon, GSK, Biohaven, and more.
Vectura Group plc confirms its R&D investment priorities, announces a proposed £50 million capital return and provides an unaudited pre-close trading update.
JOBS
IN THE PRESS